To Whom it may concern
June 20, 2024
Ohara Pharmaceutical Co., Ltd.
Additional Investment in Revital Healthcare (EPZ) Limited
Ohara Pharmaceutical Co., Ltd. Announces Increased Production Capacity for
Essential Medical Device Supplies in Africa & beyond

Ohara Pharmaceutical Co., Ltd. (President and CEO: Seiji Ohara, hereinafter referred toas "the Company") has made an additional investment in Revital Healthcare (EPZ) Limited(President: Rajni Vora, hereinafter referred to as "Revital"), the largest manufacturer of
medical devices in sub-Saharan Africa.
1. Background and Purpose
The Company is committed to supporting the growth of regionally established healthcarecompanies in Africa to address various social issues through the dissemination of quality
healthcare services and the improvement of quality of life (QOL).
In 2021, the Company partnered with the Africa Healthcare Fund (AHF-1), operated by
AAIC Investment Pte. Ltd. (headquarters: Singapore, hereinafter referred to as "AAIC"),to participate in the recapitalization of Revital. In the same year, the Bill & Melinda Gates
Foundation contributed for Revital by providing a grant of USD 4 million to innovate
Africa's first patented syringe, making Revital one of only five companies worldwide toachieve this milestone.
This year, we have decided to make an additional investment in Revital's newrecapitalization plan to expand the new manufacturing facilities for Rapid Diagnostic test
kits (RDTs) and other medical products launched in May 2024.
Revital, headquartered in Kilifi, Kenya, is a leading African manufacturer producing
medical devices such as syringes and test kits. Following our initial investment in 2021,
Revital expanded its facilities, increased production capacities for Re-Use Preventing

Ohara Pharmaceutical Co., Ltd.

syringes, and began manufacturing RDTs. During the COVID-19 pandemic, Revital
exported over 70 million vaccine syringes to 20+ countries globally, including India.
Despite these advancements, Africa's medical device sector remains heavily reliant on
imports, including test kits. To address this, Revital has invested in equipment tomanufacture RDTs for HIV, Malaria, and other infectious diseases. These efforts meet therequirements of the Kenyan government and international non-profit organizations,including the World Health Organization (WHO) and the United Nations Children's Fund(UNICEF). The new facility launched in May 2024 significantly increases supply capacity to20 million kits per month, focusing on communicable diseases such as HIV, malaria, andhepatitis. There are also plans to expand to non-communicable diseases and livestock
testing. Our additional investment will further enhance production capabilities.
Through this investment, we expect Revital to expand its capacity to supply quality
medical devices that meet regional needs and contribute to improving health standards inAfrican countries beyond Kenya.

2. The Business of Revital
Revital is the largest manufacturer of medical devices in sub-Saharan Africa, based inMombasa, Kenya. Its products have received numerous esteemed international
certifications, including WHO Performance, Quality and Safety (PQS) certification. Revitalcollaborates with the United States Agency for International Development (USAID), the Bill& Melinda Gates Foundation, and UNICEF to provide medical devices to over 40 countries
worldwide, striving to improve health standards in Africa. Notably, during the COVID-19
pandemic, Revital exported vaccine syringes globally, including to emerging Asiancountries.
On May 7, 2024, with support from USAID, Revital began producing RDTs for sub-SaharanAfrica. The new facility can manufacture 20 million test kits per month for various
diseases, including HIV, malaria, and hepatitis B/C.
Revital is constructing a new plant near its headquarters to expand its product portfolio toinclude infusion bags. In January 2024, a strategic alliance with Mitsui O.S.K. Lines, Ltd.
and MOL Logistics Co., Ltd. was signed to plan the construction of a distribution center for
medical devices and medicines in the Free Trade Area near New Mombasa Port and theOhara Pharmaceutical Co., Ltd.

International Airport. Revital will begin construction of Africa's largest healthcare kit
assembly and pharmaceutical re-packaging units.

Revital Healthcare (EPZ) Ltd•

Location: Mombasa, Kenya•

Representative: Rajni Vora•

Established: 2007•

Website: Revital Healthcare•

Business Activities: Manufacturing over 45 medical devices, including syringes(reuse-preventing, fixed-dose, and conventional), RDTs•

(e.g., coronavirus, HIV, malaria, dengue fever, syphilis), oxygen delivery systems(bCPAP), PPE kits, surgical masks, and blood transfusion kits. Certified byinternational organizations such as WHO-PQS, ISO 13485, ISO 14001, ISO 9001,
CE-TUV, WHO-GMP, US-FDA-EUA, Health Canada, NAFDAQ, MHRA, TGA.
Products recommended by UNICEF, WHO, and CHMP.

Ohara Pharmaceutical Co., Ltd•

Location: Shiga, Japan•

Representative: Seiji Ohara•

Established: 1964•

Website: Ohara Pharmaceutical•Business Activities: Discovery and manufacture of orphan and generic drugs.
Focuses on developing new drugs in core therapeutic areas such as child cancer,
hematologic cancer, CNS, and the development, manufacturing, and marketing ofgeneric drugs. Aims to provide comprehensive healthcare solutions by innovatingin treatment, prevention, diagnosis, and aftercare.

Contact information
Ohara Pharmaceutical Co., Ltd.
Representatives: Iyo
TEL: 03-6740-7701

FAX: 03-6740-7702

Ohara Pharmaceutical Co., Ltd.